MariMed (MariMed) Additional Paid-In Capital : $171.4 Mil(As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is MariMed Additional Paid-In Capital?

MariMed's quarterly additional paid-in capital increased from Sep. 2023 ($170.9 Mil) to Dec. 2023 ($171.1 Mil) and increased from Dec. 2023 ($171.1 Mil) to Mar. 2024 ($171.4 Mil).

MariMed's annual additional paid-in capital increased from Dec. 2021 ($134.9 Mil) to Dec. 2022 ($142.4 Mil) and increased from Dec. 2022 ($142.4 Mil) to Dec. 2023 ($171.1 Mil).

MariMed Additional Paid-In Capital Historical Data

The historical data trend for MariMed's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Additional Paid-In Capital Chart

MariMed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

112.25

112.97

134.92

142.37

171.14

MariMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															151.05	167.65	170.92	171.14	171.39

MariMed Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

MariMed Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of MariMed's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

MariMed (MariMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

MRMD:Canada

Address

10 Oceana Way, Floor 2, Norwood, MA, USA, 02062

Website

https://www.marimedinc.com

MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.

Executives

Jon R Levine	10 percent owner	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw	officer: Chief Operating Officer	C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker	director	C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare	officer: Chief Financial Officer	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d.	director	C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin	director	11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea	director	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman	director	310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman	director	145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc.	director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY	11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan	officer: CFO, VICE PRESIDENT	11 ROYAL RD, BROOKLINE MA 02445